文章引用说明 更多>> (返回到该文章)

V. Karavasilis, B. M. Seddon, S. Ashley, et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft- tissue sarcoma: Retrospective analysis and identification of prog- nostic factors in 488 patients. Cancer, 2008, 112(7): 1585-1591.

被以下文章引用:

  • 标题: 软组织肉瘤化疗现状及其进展Current Status and Advance of Chemotherapy for Soft Tissue Sarcoma

    作者: 佘明金, 陈振东

    关键字: 软组织肉瘤, 化学治疗Soft Tissue Sarcoma; Chemotherapy

    期刊名称: 《World Journal of Cancer Research》, Vol.2 No.2, 2012-04-28

    摘要: 软组织肉瘤(soft tissue sarcoma,STS)是来源于间叶组织和周围神经组织的异质性明显的实体恶性肿瘤,单纯手术治疗易出现复发及转移。对于高度恶性的软组织肉瘤、晚期局部广泛浸润和(或)复发转移的软组织肉瘤,化疗已成为重要的辅助治疗手段。为进一步提高疗效,新型细胞毒药物以及分子靶向药物开始应用于临床,已显示出较好的应用前景。 Soft tissue sarcoma is a kind of malignant tumor derived from mesenchymal tissue and Peripheral nerve tissue, simple treatment with surgery alone is prone to recurrence and metastasis. For highly malignant soft tissue sarcoma, locally advanced extensive infiltration and (or) recurrence and metastasis in soft tissue sarcoma, chemotherapy has become an important adjuvant treatment. To further enhance the efficacy, new cytotoxic and molecular targeted drugs have been used in clinical, and shown good application prospects.

在线客服:
对外合作:
联系方式:400-6379-560
投诉建议:feedback@hanspub.org
客服号

人工客服,优惠资讯,稿件咨询
公众号

科技前沿与学术知识分享